Fortress Biotech, Inc. Annual report pursuant to Section 13 and 15(d)

Accrued Liabilities and other Long-Term Liabilities

12 Months Ended

Dec. 31, 2017

12. Accrued Liabilities and other Long-Term Liabilities

Accrued expenses and other long-term liabilities, excluding National, consisted of the following ($ in thousands):

	December 31,
	2017		2016
Accrued expenses:
Professional fees	$	1,625	$	1,253
Salaries, bonuses and related benefits		5,279		2,846
Accrued expenses related party		95		-
Accrued severance		-		53
Ovamed manufacturing rights - short term component		-		900
Research and development		4,046		394
Dr. Falk Pharma milestone (See Note 16)		3,059		2,634
Accrued royalties payable		1,411		263
Accrued coupon expense		1,087		463
Lease impairment		-		128
Other		1,030		1,148
Total accrued expenses	$	17,632	$	10,082

Other long-term liabilities:
Deferred rent and long-term lease abandonment charge		4,739		5,014
Total other long-term liabilities	$	4,739	$	5,014

National’s accounts payable and other accrued expenses as of September 30, 2017, consisted of the following ($ in thousands):